Video

Dr. Johnson on the Clinical Potential of AMG 757 in SCLC

Melissa L. Johnson, MD, discusses the clinical potential of AMG 757 in patients with small cell lung cancer.

Melissa L. Johnson, MD, director of Lung Cancer Research at Sarah Cannon Research Institute, Tennessee Oncology, discusses the clinical potential of AMG 757 in patients with small cell lung cancer (SCLC).

AMG 757 is just one example of a novel immune mechanism that is currently being explored in SCLC, according to Johnson. Bispecifics present a promising opportunity to advance immuno-oncology in SCLC, similar to what has been done in non–small cell lung cancer with the advent of immune checkpoint inhibitors, Johnson continues. There are opportunities beyond adding an immune checkpoint inhibitor to chemotherapy in this patient population, with several innovative strategies coming down the pipeline, Johnson concludes.

Related Videos
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.
Steven H. Lin, MD, PhD
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.